First patients enrolled in Phase I trial with KQB548, an investigational KRAS inhibitor designed to treat KRAS G12D-mutated tumors
The company plans to use the funds raised from the net proceeds to repay or prepay certain loans
New filling line approval supports delivery of integrated, end-to-end solutions across the entire biologics and bioconjugates value chain
Furthering?U.S.-based?pharmaceutical?capacity?to?produce?critical respiratory medicines?
Datroway becomes the first and only therapy to show overall survival benefit versus chemotherapy in this difficult-to-treat patient population
Stephan brings more than 20 years of leadership experience in the pharmaceutical industry
These products strengthen poultry immunity, improve productivity, and support sustainable farming practices~
Lonza boosts TheraPEAK line with new Cytokines and AAV Medium for next-gen therapies
Investment to expand manufacturing and global medicine supply capacity
Combination reduced the risk of disease progression or death by 46% and risk of death by 27% in pivotal phase III IMforte study
Subscribe To Our Newsletter & Stay Updated
